

1 *N*<sup>6</sup>-methyladenosine modification and the YTHDF2 reader protein play cell type  
2 specific roles in lytic viral gene expression during Kaposi's sarcoma-associated  
3 herpesvirus infection

4

5 Charles Hesser<sup>1</sup>, John Karijolic<sup>2,3</sup>, Dan Dominissini<sup>4,5,6</sup>, Chuan He<sup>4,7</sup>, and Britt Glaunsinger<sup>1,2,7</sup>

6 <sup>1</sup>Department of Molecular and Cell Biology, <sup>2</sup>Department of Plant & Microbial Biology,  
7 University of California Berkeley; <sup>3</sup>Department of Pathology, Microbiology, and Immunology,  
8 Vanderbilt University Medical Center, Nashville, TN 37232-2363, <sup>4</sup>Department of Chemistry,  
9 Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, The  
10 University of Chicago, Chicago, Illinois, USA; <sup>5</sup>Chaim Sheba Medical Center, Tel Hashomer  
11 52621, Israel; <sup>6</sup>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>7</sup>Howard Hughes  
12 Medical Institute

13

14 \*Corresponding author: [glaunsinger@berkeley.edu](mailto:glaunsinger@berkeley.edu)

15

16

17 **Abstract**

18 Methylation at the  $N^6$  position of adenosine ( $m^6A$ ) is a highly prevalent and reversible  
19 modification within eukaryotic mRNAs that has been linked to many stages of RNA processing  
20 and fate. Recent studies suggest that  $m^6A$  deposition and proteins involved in the  $m^6A$  pathway  
21 play a diverse set of roles in either restricting or modulating the lifecycles of select viruses.  
22 Here, we report that  $m^6A$  levels are significantly increased in cells infected with the oncogenic  
23 human DNA virus Kaposi's sarcoma-associated herpesvirus (KSHV). Transcriptome-wide  $m^6A$ -  
24 sequencing of the KSHV-positive renal carcinoma cell line iSLK.219 during lytic reactivation  
25 revealed the presence of  $m^6A$  across multiple kinetic classes of viral transcripts, and a  
26 concomitant decrease in  $m^6A$  levels across much of the host transcriptome. However, we found  
27 that depletion of the  $m^6A$  machinery had differential pro- and anti-viral impacts on viral gene  
28 expression depending on the cell-type analyzed. In iSLK.219 and iSLK.BAC16 cells the pathway  
29 functioned in a pro-viral manner, as depletion of the  $m^6A$  writer METTL3 and the reader  
30 YTHDF2 significantly impaired virion production. In iSLK.219 cells the defect was linked to their  
31 roles in the post-transcriptional accumulation of the major viral lytic transactivator ORF50,  
32 which is  $m^6A$  modified. In contrast, although the ORF50 mRNA was also  $m^6A$  modified in KSHV  
33 infected B cells, ORF50 protein expression was instead increased upon depletion of METTL3, or,  
34 to a lesser extent, YTHDF2. These results highlight that the  $m^6A$  pathway is centrally involved in  
35 regulating KSHV gene expression, and underscore how the outcome of this dynamically  
36 regulated modification can vary significantly between cell types.

37

## 38 **Author Summary**

39 In addition to its roles in regulating cellular RNA fate, methylation at the  $N^6$  position of  
40 adenosine ( $m^6A$ ) of mRNA has recently emerged as a mechanism for regulating viral infection.  
41 While it has been known for over 40 years that the mRNA of nuclear replicating DNA viruses  
42 contain  $m^6A$ , only recently have studies begun to examine the distribution of this modification  
43 across viral transcripts, as well as characterize its functional impact upon viral lifecycles. Here,  
44 we apply  $m^6A$ -sequencing to map the location of  $m^6A$  modifications throughout the  
45 transcriptome of the oncogenic human DNA virus Kaposi's sarcoma-associated herpesvirus  
46 (KSHV). We show that the  $m^6A$  machinery functions in a cell type specific manner to either  
47 promote or inhibit KSHV gene expression. Thus, the KSHV lifecycle is impacted by the  $m^6A$   
48 pathway, but the functional outcome may depend on cell lineage specific differences in  $m^6A$ -  
49 based regulation.

50

## 51 **Introduction**

52 The addition of chemical modifications is critical to many steps of mRNA processing and  
53 the regulation of mRNA fate. There are more than 100 different RNA modifications, but the  
54 most abundant internal modification of eukaryotic mRNAs is  $N^6$ -methyladenosine ( $m^6A$ ), which  
55 impacts nearly every stage of the posttranscriptional mRNA lifecycle from splicing through  
56 translation and decay [1-6]. The breadth of impacts ascribed to the  $m^6A$  mark can be attributed  
57 to its creation of new platforms for protein recognition, in part via local changes to the RNA  
58 structure [4,7-12]. The reversibility of  $m^6A$  deposition through the activity of demethylases

59 termed erasers adds a further layer of complexity by enabling dynamic regulation, for example  
60 during developmental transitions and stress [1,4,5,13-15]. Deposition of m<sup>6</sup>A occurs co- or post-  
61 transcriptionally through a complex of proteins with methyltransferase activity known as  
62 writers, which include the catalytic subunit METTL3 and cofactors such as METTL14 and WTAP  
63 [1,4,14,16,17]. The modification is then functionally ‘interpreted’ through the selective binding  
64 of m<sup>6</sup>A reader proteins, whose interactions with the mRNA promote distinct fates.

65         The best-characterized m<sup>6</sup>A readers are the YTH domain proteins. The nuclear YTHDC1  
66 reader promotes exon inclusion [6], whereupon m<sup>6</sup>A-containing mRNA fate is guided in the  
67 cytoplasm by the YTHDF1-3 readers. Generally speaking, YTHDF1 directs mRNAs with 3’ UTR  
68 m<sup>6</sup>A modifications to promote translation [3], whereas YTHDF2 recruits the CCR4-NOT  
69 deadenylase complex to promote mRNA decay [18]. YTHDF3 has been proposed to serve as a  
70 co-factor to potentiate the effects of YTHDF1 and 2 [3,19,20]. Although the individual effects of  
71 YTHDF1 and 2 seem opposing, the YTHDF proteins may coordinate to promote accelerated  
72 mRNA processing during developmental transitions and cellular stress [1]. YTHDC2, the fifth  
73 member of the YTH family proteins, was recently shown to play critical roles in mammalian  
74 spermatogenesis through regulating translation efficiency of target transcripts [21]. Additional  
75 examples of distinct functions for m<sup>6</sup>A readers under specific contexts such as heat shock are  
76 rapidly emerging [13].

77         Given the prevalence of the m<sup>6</sup>A modification on cellular mRNAs, it is not surprising that  
78 a number of viruses have been shown to contain m<sup>6</sup>A in their RNA [22-29]. Indeed, a potential  
79 viral benefit could be a less robust innate antiviral immune response, as m<sup>6</sup>A modification of in  
80 vitro synthesized RNAs diminishes recognition by immune sensors such as TLR3 and RIG-I

81 [30,31]. That said, the functional consequences of viral mRNA modification appear diverse and  
82 include both pro- and anti-viral roles. In the case of Influenza A, a negative sense ssRNA virus,  
83 m<sup>6</sup>A and the reader YTHDF2 have been shown to promote viral replication [32]. Furthermore,  
84 multiple studies have mapped the sites of m<sup>6</sup>A modification in the human immunodeficiency  
85 virus (HIV) genome, and shown that it promotes the nuclear export of HIV mRNA as well as viral  
86 protein synthesis and RNA replication [24,26,28]. Roles for the YTHDF proteins in during HIV  
87 infection remain varied however, as Tirumuru and colleagues propose they function in an anti-  
88 viral context by binding viral RNA and inhibiting reverse transcription, while Kennedy and  
89 colleagues observe they enhance HIV replication and viral titers [24,28]. A more consistently  
90 anti-viral role for the m<sup>6</sup>A pathway has been described for the *Flaviviridae*, whose (+) RNA  
91 genomes are replicated exclusively in the cytoplasm and contain multiple m<sup>6</sup>A sites in their  
92 genomic RNA [23,25]. An elegant study by Horner and colleagues showed that depletion of m<sup>6</sup>A  
93 writers and readers or the introduction of m<sup>6</sup>A-abrogating mutations in the viral E1 gene all  
94 selectively inhibit hepatitis C virus (HCV) assembly [23]. Similarly, depletion of METTL3 or  
95 METTL14 enhances Zika virion production [25].

96         Despite the fact that m<sup>6</sup>A modification of DNA viruses was first reported more than 40  
97 years ago for simian virus 40, herpes simplex virus type 1, and adenovirus type 2, roles for the  
98 modification in these and other DNA viruses remain largely unexplored [33-37]. Unlike most  
99 RNA viruses, with few exceptions DNA viruses replicate in the nucleus and rely on the cellular  
100 transcription and RNA processing machinery, indicating their gene expression strategies are  
101 likely interwoven with the m<sup>6</sup>A pathway. Indeed, it was recently shown that the nuclear reader  
102 YTHDC1 potentiates viral mRNA splicing during lytic infection with Kaposi's sarcoma-associated

103 herpesvirus (KSHV) [38]. Furthermore, new evidence suggests m<sup>6</sup>A modification potentiates the  
104 translation of late SV40 mRNAs [39], further indicating that this pathway is likely to exert a wide  
105 range of effects on viral lifecycles.

106 Here, we sought to address roles for the m<sup>6</sup>A pathway during lytic KSHV infection by  
107 measuring and mapping the abundance of m<sup>6</sup>A marks across the viral and host transcriptome.  
108 This gammaherpesvirus remains the leading etiologic agent of cancer in AIDS patients, in  
109 addition to causing the lymphoproliferative disorders multicentric Castleman's disease and  
110 primary effusion lymphoma. The default state for KSHV in cultured cells is latency, although in  
111 select cell types the virus can be reactivated to engage in lytic replication, which involves a  
112 temporally ordered cascade of gene expression. We reveal that m<sup>6</sup>A levels are significantly  
113 increased upon KSHV reactivation, which is due to a combination of m<sup>6</sup>A deposition across  
114 multiple kinetic classes of viral transcripts and a concomitant decrease in m<sup>6</sup>A levels across  
115 much of the host transcriptome. Depletion of m<sup>6</sup>A writer and cytoplasmic reader proteins  
116 impaired viral lytic cycle progression in the KSHV iSLK.219 and iSLK.BAC16 reactivation models,  
117 suggesting this pathway potentiates the KSHV lytic cycle. Interestingly, however, the roles for  
118 the m<sup>6</sup>A writer and readers shifted to instead display neutral or anti-viral activity in the TREX-  
119 BCBL-1 reactivation model. These findings thus demonstrate that while KSHV mRNAs are  
120 marked by m<sup>6</sup>A, the functional consequences of this mark can vary significantly depending on  
121 cell context, reinforcing both the functional complexity and dynamic influence of m<sup>6</sup>A.

122

123 **Results**

## 124 KSHV mRNA contains m<sup>6</sup>A modifications

125 Epitranscriptome mapping has revealed significant roles for the m<sup>6</sup>A pathway in the  
126 lifecycle and regulation of several RNA viruses, but at the time we initiated these studies,  
127 similar global analyses had yet to be performed for a DNA virus. Given that herpesviral mRNAs  
128 are transcribed and processed in the nucleus using the cellular RNA biogenesis machinery, we  
129 hypothesized that these viruses would engage the m<sup>6</sup>A pathway. We therefore first quantified  
130 how KSHV reactivation impacted total cellular m<sup>6</sup>A levels in the KSHV-positive renal carcinoma  
131 cell line iSLK.219 (**Fig 1**). These cells are a widely used model for studying viral lytic events, as  
132 they stably express the KSHV genome in a tightly latent state but harbor a doxycycline (dox)-  
133 inducible version of the major viral lytic transactivator ORF50 (also known as RTA) that enables  
134 efficient entry into the lytic cycle [40,41]. Polyadenylated (polyA+) RNA was enriched from  
135 untreated (latent) or dox-reactivated iSLK.219 cells and the levels of m<sup>6</sup>A were quantitatively  
136 analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (**Fig 1A**). Indeed,  
137 we observed a three-fold increase in total m<sup>6</sup>A levels upon KSHV lytic reactivation, suggesting  
138 that m<sup>6</sup>A deposition significantly increased during viral replication (**Fig 1B**).

139 We next sought to discern whether the increase in m<sup>6</sup>A during the KSHV lytic cycle  
140 favors host or viral mRNAs using high throughput m<sup>6</sup>A RNA sequencing (m<sup>6</sup>A-seq) [42]. This  
141 technique can reveal both the relative abundance and general location of m<sup>6</sup>A in KSHV and  
142 cellular mRNA. Total m<sup>6</sup>A containing RNA was immunoprecipitated from 2 biological replicates  
143 of latent or lytically reactivated iSLK.219 cells using an m<sup>6</sup>A-specific antibody. DNase-treated  
144 total mRNA was fragmented to lengths of 100 nt prior to immunoprecipitation and then

145 subjected to m<sup>6</sup>A-seq. Total RNA-seq was run in parallel for each sample, allowing the degree of  
146 m<sup>6</sup>A modification to be normalized with respect to transcript abundance because the levels of  
147 many transcripts change upon viral lytic reactivation. Peaks with a fold-change four or higher  
148 (FC>4) and a false discovery rate of 5% or lower (FDR>5%) in both replicates were considered  
149 significant, although it is possible that additional transcripts detectably modified to lower levels  
150 or in a more dynamic manner may also be functionally regulated by m<sup>6</sup>A (complete list of viral  
151 peaks with FC>2 in **S1 Table**). In lytically reactivated samples, 10 transcripts comprising genes of  
152 immediate early, early, and late kinetic classes displayed significant m<sup>6</sup>A modification in both  
153 replicates (**Fig 2A** and **S1 Fig**). Within these KSHV mRNAs, m<sup>6</sup>A peaks were detected primarily in  
154 coding regions, although in some cases the location of a peak in a coding region overlaps with a  
155 UTR (**S1 Fig**). Furthermore, all but one peak contains at least one instance of the GG(m<sup>6</sup>A)C  
156 consensus sequence. While many of the modified viral transcripts contained only one m<sup>6</sup>A  
157 peak, multiple peaks were found in certain transcripts, including the major lytic transactivator  
158 ORF50 (**Fig 2B**). Of note, exon2 of ORF50 contained one m<sup>6</sup>A peak of FC>4 in replicate one, and  
159 three m<sup>6</sup>A peaks in replicate two, each of which have at least one m<sup>6</sup>A consensus motif, further  
160 increasing confidence that these peaks accurately represent m<sup>6</sup>A modified sites. Furthermore,  
161 the viral ncRNA PAN, which has been reported to comprise over 80% of nuclear PolyA+ RNA  
162 during lytic reactivation [43], contains FC>4 peaks in both replicates. Modification of PAN likely  
163 accounts for the marked three-fold increase in cellular m<sup>6</sup>A content observed upon lytic  
164 reactivation (**Fig 1B**). As anticipated given the restricted viral gene expression profile during  
165 latency, unreactivated samples had many fewer m<sup>6</sup>A containing viral mRNAs, with the only  
166 FC>4 peaks occurring in both replicates located in ORF4. Although ORF4 is a lytic transcript, its



167 coding region overlaps with the 3' UTR of K1, which is expressed during both the latent and lytic  
168 phases of the viral lifecycle (**Fig 2A, S1 Fig**) [44,45].

169 To validate the m<sup>6</sup>A-seq results, we performed m<sup>6</sup>A RNA immunoprecipitation (RIP)  
170 followed by quantitative real-time PCR (RT-qPCR) on six of the viral transcripts predicted to be  
171 m<sup>6</sup>A modified from the m<sup>6</sup>A-seq data. This technique allows determination of the relative level  
172 of m<sup>6</sup>A content in a given transcript compared to an unmodified transcript. As controls, we  
173 included primers for the cellular GAPDH transcript, which is known not to be m<sup>6</sup>A modified, and  
174 the Dicer transcript, which is m<sup>6</sup>A modified [42]. The m<sup>6</sup>A RIP RT-qPCR confirmed modification  
175 of the vIL-6, K1, ORF50, ORF57 and PAN viral transcripts, in agreement with m<sup>6</sup>A-seq results (**Fig**  
176 **2C**). In summary, we found m<sup>6</sup>A modification in approximately one third of KSHV transcripts  
177 upon lytic reactivation, consistent with the hypothesis that this pathway contributes to KSHV  
178 gene expression.

179 We next compared the distribution of m<sup>6</sup>A peaks in host mRNAs from unreactivated  
180 versus reactivated cells to assess whether lytic KSHV infection altered the m<sup>6</sup>A profile of cellular  
181 transcripts. Analyzing the two independent replicates for each condition, we found an average  
182 of 14,092 m<sup>6</sup>A modification sites (FC>4 and FDR>5%) in host transcripts pre-reactivation,  
183 compared to 10,537 peaks post-reactivation (**Fig 2D and S2 Table**). We observed that this >25%  
184 decrease in m<sup>6</sup>A deposition on cellular mRNA encompassed a wide spectrum of transcripts, and  
185 no notable patterns were apparent by GO term analysis for functional categories enriched in  
186 the altered population. Thus, while the functional impact of the altered host m<sup>6</sup>A profile  
187 remains unresolved, the observation that KSHV lytic infection increased the level of m<sup>6</sup>A in total  
188 poly A+ RNA despite decreasing its presence in cellular mRNA implies that m<sup>6</sup>A deposition

189 during infection favors viral transcripts.

190

191 **m<sup>6</sup>A and the reader YTHDF2 mediate viral gene expression and virion production in iSLK.219**

192 **cells**

193         Given the significant deposition of m<sup>6</sup>A across KSHV transcripts, we reasoned that m<sup>6</sup>A  
194 might play an important role in potentiating the viral lifecycle. We therefore examined the  
195 effect of depleting the m<sup>6</sup>A writers and readers on KSHV virion production using a supernatant  
196 transfer assay. The KSHV genome in iSLK.219 cells contains a constitutively expressed version of  
197 GFP, which allows for fluorescence-based monitoring of infection by progeny virions. We  
198 performed siRNA-mediated knockdown of METTL3, the catalytic subunit responsible for m<sup>6</sup>A  
199 deposition, as well as the m<sup>6</sup>A readers YTHDF 1, 2 and 3 (**Fig 3A**). Cells were then treated with  
200 dox and sodium butyrate to induce lytic reactivation for 72 h, whereupon supernatants were  
201 collected and used to infect 293T recipient cells. The number of GFP positive 293T cells at 24  
202 hpi was measured by flow cytometry (**Fig 3B**). Notably, for virus generated from METTL3  
203 depleted cells, only 7% of recipient cells were infected compared to 82% for virus generated  
204 during treatment with a control siRNA (**Fig 3B**). YTHDF2 depletion caused an even more  
205 pronounced defect, resulting in a near absence of virion production (**Fig 3B**). In contrast,  
206 YTHDF3 knockdown resulted in only modest changes in virion production, while virion  
207 production was unaffected by YTHDF1 knockdown (**Fig 3B**). The prominent defect in virion  
208 production in METTL3 and YTHDF2 depleted cells was not due to knockdown-associated  
209 toxicity, as we did not observe changes in cell viability in siRNA treated cells (representative

210 experiment shown in **S2 Fig**). Furthermore, we validated the results for YTHDF2 and YTHDF3  
211 using independent siRNAs (**S2 Fig**). Thus, the m<sup>6</sup>A writer METTL3 and the reader YTHDF2 play  
212 important roles in driving KSHV infectious virion production in iSLK.219 cells.

213 We then sought to determine the stage of the viral lifecycle impacted by the m<sup>6</sup>A  
214 pathway by measuring the impact of writer and reader depletion on the abundance of viral  
215 mRNAs of different kinetic classes. First, levels of representative immediate early, delayed  
216 early, and late viral mRNAs were measured by RT-qPCR following lytic reactivation for 72 hr.  
217 ORF50 and K8.1 transcripts contained at least one m<sup>6</sup>A peak, while ORF37 did not appear to be  
218 significantly modified in our m<sup>6</sup>A-seq data (see **S1 Table**). METTL3 depletion did not appear to  
219 impact accumulation of the ORF50 immediate early or ORF37 delayed early mRNAs at this time  
220 point, but resulted in a significant defect in accumulation of the K8.1 late gene mRNA (**Fig 3C**).  
221 Consistent with the virion production data, we observed a striking and consistent defect in the  
222 accumulation of each of the viral transcripts upon YTHDF2 depletion, suggesting that this  
223 protein is essential for lytic KSHV gene expression beginning at the immediate early stage (**Fig**  
224 **3C**). Similar results were observed using an independent YTHDF2-targeting siRNA (**S2 Fig**). We  
225 also observed a prominent defect in accumulation of ORF50 and the delayed early ORF59  
226 proteins by Western blot specifically upon YTHDF2 depletion (**Fig 3D**). In contrast, depletion of  
227 YTHDF1 or YTHDF3 did not reproducibly impact ORF50, ORF37, or K8.1 gene expression at 72 h  
228 post reactivation (**Fig 3C**).

229 In agreement with the above findings, we also observed that iSLK.219 cells depleted of METTL3  
230 and YTHDF2 displayed a prominent defect in viral reactivation, as measured by expression of  
231 red fluorescent protein (RFP) driven by the PAN lytic cycle promoter from the viral genome (**Fig**

232 **3E**). Similarly, ORF50 protein production was also markedly reduced upon METTL3 or YTHDF2  
233 depletion at the 24 h time point, which represents the early phase of the lytic cycle (**Fig 3F**).  
234 To determine whether the effects of the m<sup>6</sup>A pathway on ORF50 were dependent on KSHV  
235 infection, we measured ORF50 protein in an uninfected iSLK cell line containing only the  
236 integrated, dox-inducible ORF50 gene (iSLK.puro cells) (**Fig 3G**). Similar to our findings with  
237 infected iSLK.219 cells, depletion of METTL3 or YTHDF2 strongly reduced ORF50 protein levels  
238 (**Fig 3H**). YTHDF3 depletion resulted in an increase in ORF50 expression, which we also observed  
239 to a more modest degree in the iSLK.219 cells (see **Fig 3D**). Collectively, these results suggest  
240 that m<sup>6</sup>A modification is integral to the KSHV lifecycle, and that YTHDF2 plays a particularly  
241 prominent role in mediating KSHV lytic gene expression in iSLK.219 cells. They further indicate  
242 that m<sup>6</sup>A modification can impact ORF50 expression in both uninfected and KSHV infected iSLK  
243 cells.

244

245 **The m<sup>6</sup>A pathway post-transcriptionally controls ORF50 expression in iSLK.219 cells, leading**  
246 **to a subsequent defect in transcriptional feedback at the ORF50 promoter.**

247 ORF50 is the major viral transcriptional transactivator, and its expression is essential to  
248 drive the KSHV lytic gene expression cascade [46]. The observations that ORF50 is m<sup>6</sup>A modified  
249 and that its accumulation is dependent on YTHDF2 indicate that the m<sup>6</sup>A pathway plays key  
250 roles in ORF50 mRNA biogenesis or fate in iSLK.219 cells, potentially explaining the lytic cycle  
251 progression defect in the knockdown cells. Deposition of m<sup>6</sup>A has been reported to occur both  
252 co-transcriptionally and post-transcriptionally [1,16,17,47]. To determine whether the m<sup>6</sup>A

253 pathway is important for ORF50 synthesis or its posttranscriptional fate, we measured ORF50  
254 transcription in reactivated iSLK.219 cells upon depletion of METTL3, YTHDF2, or YTHDF3 using  
255 4-thiouridine (4sU) metabolic pulse labeling. 4sU is a uridine derivative that is incorporated into  
256 RNA during its transcription, and thiol-specific biotinylation of the 4sU-containing RNA enables  
257 its purification over streptavidin-coated beads [48,49]. At 24 h post reactivation, RNA in the  
258 siRNA treated iSLK.219 cells was pulse labeled with 4sU for 30 min, whereupon the labeled RNA  
259 was isolated by biotin-streptavidin purification and viral transcripts were quantified by RT-qPCR  
260 (**Fig 4A**). Despite the defect in ORF50 accumulation observed upon YTHDF2 depletion (see **Fig**  
261 **3F**), we observed no decrease in 4sU-labeled ORF50 mRNA upon depletion of any of the m<sup>6</sup>A  
262 writer or reader proteins (**Fig 4B**). However, in YTHDF2 depleted cells, there was a prominent  
263 defect in the level of 4sU-labeled ORF37, likely because its transcription is dependent on the  
264 presence of ORF50 protein (**Fig 4C**).

265         The ORF50 mRNA detected in the above experiments represents a combination of the  
266 mRNA transcribed from the dox-inducible cassette as well as from the KSHV genome [41].  
267 While the dox-inducible promoter is constitutively active under dox treatment, ORF50  
268 transcription from KSHV is sensitive to ORF50 protein levels because it transactivates its own  
269 promoter [50]. The decreased ORF50 protein levels observed in Fig 3 might therefore lead to a  
270 selective reduction in transcription from the native ORF50 promoter by interfering with this  
271 positive transcriptional feedback. Indeed, primers designed to specifically recognize ORF50  
272 derived from the viral genome revealed a marked defect in transcription of KSHV-derived  
273 ORF50 upon YTHDF2 depletion, as well as a slight reduction upon METTL3 depletion (**Fig 4D**).  
274 Collectively, the above results suggest that m<sup>6</sup>A initially functions to post-transcriptionally

275 regulate ORF50 mRNA abundance, but that when ORF50 protein levels fall upon YTHDF2 or  
276 METTL3 knockdown, the positive transcriptional feedback mechanism at the viral promoter also  
277 becomes restricted.

278

### 279 **The impact of m<sup>6</sup>A on KSHV infection is cell type specific**

280 To independently validate the METTL3 and YTHDF2 phenotypes, we also evaluated their  
281 importance in the iSLK.BAC16 model. Although independently generated, this is the same cell  
282 background as iSLK.219, including the dox-inducible ORF50, but instead contains the viral  
283 genome in the context of a bacterial artificial chromosome (BAC16) [51]. Similar to our results  
284 with the infected iSLK.219 cells, depletion of METTL3 or YTHDF2 in iSLK.BAC16 cells led to a  
285 significant defect in virion production as measured by supernatant transfer assays (**Fig 5A-C**). In  
286 addition, the total levels of ORF50 mRNA (from the dox-induced plus viral promoters) were  
287 unchanged between the different siRNA treated cells, while depletion of YTHDF2 led to a  
288 significant reduction in the level of BAC16-derived ORF50 and K8.1 mRNAs (**Fig 5D**). In contrast,  
289 METTL3 depletion did not significantly impact the level of ORF50, ORF37, or K8.1 transcripts. It  
290 should be noted that levels of METTL3 knockdown in excess of 80% have only been reported to  
291 reduce m<sup>6</sup>A levels in Poly A RNA by 20-30% [17]. Thus, at least some fraction of ORF50 (and  
292 other) transcripts may still be m<sup>6</sup>A modified due to residual enzyme activity of the remaining  
293 METTL3. In agreement with these observations, knockdown of METTL3 modestly reduced but  
294 did not eliminate the pool of m<sup>6</sup>A modified ORF50 or the cellular SON mRNAs in iSLK.BAC16  
295 cells as measured by m<sup>6</sup>A RIP RT-qPCR (**S3 Fig**). Finally, we observed that although ORF59

296 protein levels were consistently reduced upon YTHDF2 knockdown, and to a more variable  
297 extent upon METTL3 depletion, we did not detect the same marked effects on ORF50 protein  
298 levels in iSLK.BAC16 cells as in iSLK.219 cells (**Fig 5E**). In summary, although iSLK.219 and  
299 iSLK.BAC16 cells exhibit a somewhat different gene expression profile in the context of YTHDF2  
300 and METTL3 knockdown, depletion of these m<sup>6</sup>A pathway components restricts the KSHV lytic  
301 lifecycle in both models.

302 Given the diversity of functions reported for m<sup>6</sup>A in controlling cellular processes and virus  
303 infections [1,22,27], we also sought to evaluate the role of this pathway in mediating ORF50  
304 expression in another widely used KSHV infected cell line of distinct origin, the B cell line TREX-  
305 BCBL-1 [52]. Similar to iSLK.219 and iSLK.BAC16 cells, TREX-BCBL-1 cells also contain a dox-  
306 inducible copy of ORF50 to boost reactivation. First, we evaluated whether the ORF50  
307 transcript was m<sup>6</sup>A modified in TREX-BCBL-1 cells by m<sup>6</sup>A RIP, followed by RT-qPCR using  
308 control or ORF50 specific primers. Indeed, there was a clear enrichment of ORF50 in the  
309 reactivated, m<sup>6</sup>A-containing RNA population (**Fig 6A**). As expected, we detected the m<sup>6</sup>A  
310 modified DICER transcript in both reactivated and unreactivated cells, whereas the unmodified  
311 GAPDH transcript was present in neither sample (**Fig 6A**).

312 The m<sup>6</sup>A pathway components were then depleted from TREX-BCBL-1 cells via siRNA treatment,  
313 whereupon cells were reactivated for 72 hr with dox, TPA, and ionomycin. As knockdown  
314 efficiency for YTHDF1 was inconsistent in this cell type, we focused on the impact of METTL3,  
315 YTHDF2, and YTHDF3. We observed no significant changes in the level of ORF50 mRNA upon  
316 METTL3 or YTHDF3 depletion (**Fig 6B, D**). Although there was a consistent decrease in ORF50  
317 mRNA in the YTHDF2 depleted cells, this may be due to the fact that YTHDF2 knockdown

318 modestly decreased the viability of TREX-BCBL1 cells (**S4 Fig**). Surprisingly, however, METTL3  
319 knockdown and, to a more variable extent YTHDF2 knockdown, resulted in increased ORF50  
320 protein expression (**Fig 6C**, additional replicate experiments showing ORF50 levels in **S4 Fig**).  
321 YTHDF3 depletion did not significantly impact ORF50 or ORF59 protein (**Fig 6C**). Thus, unlike in  
322 iSLK cells, METTL3 and YTHDF2 appear to restrict ORF50 expression in TREX-BCBL1 cells. These  
323 phenotypic differences were not due to distinct virus-induced alterations in the abundance of  
324 METTL3, YTHDF2, or YTHDF3, as levels of these proteins remained consistent following lytic  
325 reactivation in TREX-BCBL1, iSLK.219, and iSLK.BAC16 cells (**S5 Fig**).

326 Finally, to determine whether the m<sup>6</sup>A pathway components impacted the outcome of the viral  
327 lifecycle in TREX-BCBL1 cells, we measured the impact of METTL3, YTHDF2, and YTHDF3 protein  
328 knockdown on virion production using a supernatant transfer assay. TREX-BCBL-1 cells lack the  
329 viral GFP marker, and thus infection of recipient cells was instead measured by RT-qPCR for the  
330 KSHV latency-associated LANA transcript. Again in contrast to the iSLK cell data, we observed  
331 that METTL3, YTHDF2, and YTHDF3 were dispensable for virion production in TREX-BCBL-1 cells  
332 (**Fig 6E**). Instead, METTL3 depletion consistently resulted in a modest, though not statistically  
333 significant, increase in the level of LANA mRNA in the recipient cells (**Fig 6E**). In summary,  
334 METTL3 and YTHDF2 appear to function in a pro-viral capacity and promote ORF50 expression  
335 in iSLK.219 and iSLK.BAC16 cells, but instead restrict ORF50 expression in TREX-BCBL-1 cells.  
336 These findings highlight how at least a subset of m<sup>6</sup>A pathway functions and targets may  
337 diverge between cell types.

338



## 339 Discussion

340 Although m<sup>6</sup>A modification of viral RNAs has been recognized for more than 40 years,  
341 only recently are the contributions of this epitranscriptomic mark towards viral life cycles  
342 beginning to be revealed. Thus far, global epitranscriptomic analyses have documented m<sup>6</sup>A  
343 deposition during infections with KSHV, SV40, HIV, Influenza A virus and several members of  
344 the *Flaviviridae*, with a diverse set of resulting pro- and anti-viral roles [23-26,28,32,39,53]. The  
345 breadth and occasionally apparently contrasting functions for the m<sup>6</sup>A pathway during infection  
346 are perhaps unsurprising given the dynamic role for this modification in controlling mRNA fate  
347 and its ability to impact virtually every stage of host gene expression [1,27]. Our global analysis  
348 of the m<sup>6</sup>A epitranscriptome during lytic infection with the DNA virus KSHV showed the  
349 presence of m<sup>6</sup>A across multiple kinetic classes of viral transcripts and a general decrease in  
350 m<sup>6</sup>A deposition on cellular mRNAs. In the widely used KSHV-positive cell lines iSLK.219 and  
351 iSLK.BAC16, we found that depletion of several components of the m<sup>6</sup>A pathway inhibited the  
352 KSHV lytic cycle, most notably in iSLK.219 cells by restricting accumulation of the viral lytic  
353 transactivator ORF50. The YTHDF2 reader protein proved particularly important, as its  
354 depletion eliminated lytic entry and virion production. These observations are suggestive of a  
355 pro-viral role for m<sup>6</sup>A in the iSLK.219 and iSLK.BAC16 KSHV reactivation models. However, m<sup>6</sup>A  
356 marks on mRNA in a cell are widespread and contribute to a large variety of cellular and  
357 pathogenic processes that likely occur in a cell type or context-dependent manner. In this  
358 regard, it is notable that a distinct set of phenotypes was observed for m<sup>6</sup>A pathway  
359 components in the B cell line TREG-BCBL-1. Here, depletion of METTL3 and YTHDF2 increased  
360 ORF50 abundance, more suggestive of an anti-viral role. Thus, although KSHV engages the m<sup>6</sup>A

361 pathway in multiple cell types, these findings underscore the importance of not broadly  
362 extrapolating m<sup>6</sup>A roles from a particular cell type, as this complex regulatory pathway can  
363 functionally vary in a cell type dependent manner.

364           What might be the basis for these phenotypic differences between cell types in the  
365 context of KSHV infection? m<sup>6</sup>A deposition was also recently reported in many KSHV mRNAs in  
366 BCBL-1 cells, including ORF50 [38]. Furthermore, while this work was in revision, Tan and  
367 colleagues documented extensive modification of KSHV transcripts during latent KSHV infection  
368 of multiple cell types, as well as upon lytic infection of iSLK.BAC16 and TREX-BCBL-1 cells [53].  
369 Notably, while numerous differences were found in the cellular m<sup>6</sup>A profiles between the two  
370 cell lines, many peaks in viral transcripts were consistent across cell types, including two out of  
371 three m<sup>6</sup>A peaks in ORF50 [53]. In agreement with these studies, we also observed extensive  
372 modification of KSHV mRNAs, and observed that ORF50 is modified in iSLK.BAC16 cells, iSLK.219  
373 cells and TREX-BCBL-1 cells. Thus, it is not the case that the viral mRNAs engage the m<sup>6</sup>A  
374 methyltransferase machinery in one cell type but not the other, although it is clear that site  
375 specificity of m<sup>6</sup>A deposition, particularly in host mRNAs, can vary between cell lines. The facts  
376 that m<sup>6</sup>A deposition is dynamic and does not strictly occur on consensus motifs render this  
377 possibility challenging to resolve. Indeed, how m<sup>6</sup>A deposition selectively controls gene  
378 regulation on particular transcripts or under particular stimuli remains a central unanswered  
379 question in the field [1]. We hypothesize that the distinct phenotypes derive either from how  
380 the viral modifications are 'interpreted' in each cell type and/or indirect effects driven by an  
381 altered m<sup>6</sup>A profile on cellular mRNAs. The recent finding that m<sup>6</sup>A modification of ORF50 in  
382 BCBL-1 cells contributes to efficient splicing through binding of YTHDC1 argues that

383 modifications can have a direct cis-acting impact on KSHV mRNA fate [38]. However,  
384 herpesviral mRNAs are heavily reliant on host machinery at every stage of their biogenesis.  
385 Given that cellular mRNA fate is significantly altered upon depletion of METTL3 and the YTHDF  
386 reader proteins [1-3,18,54], it is possible that cell type specific changes in the abundance of a  
387 host factor(s) required for viral mRNA stability also contribute to the phenotypic differences.  
388 Furthermore, in HIV infected cells m<sup>6</sup>A modification and YTHDF proteins have been proposed to  
389 have a combination of pro-viral and anti-viral effects, including negatively impacting reverse  
390 transcription, enhancing mRNA export, and increasing viral protein production [24,26,28].  
391 Therefore, the m<sup>6</sup>A pathway might similarly facilitate distinct phenotypes at different stages of  
392 the KSHV lifecycle.

393         Although our m<sup>6</sup>A-seq results are in agreement with the recent report from Tan and  
394 colleagues, our data on the role of YTHDF2 in iSLK.BAC16 cells differs from theirs [53]. They did  
395 not evaluate the impact of METTL3 depletion, but reported that YTHDF2 depletion increased  
396 KSHV replication in these cells. In contrast, we observed a significant reduction in virion  
397 production upon depletion of YTHDF2 in both iSLK.219 and iSLK.BAC16 cells. Given the  
398 similarity in approaches used to evaluate the impact of YTHDF2, the basis for these differences  
399 remains unclear. However, our experiments comparing the iSLK.219 and iSLK.BAC16 cells  
400 indicates that even in cell lines of the same origin there can be differences in the m<sup>6</sup>A-  
401 associated viral gene expression signatures.

402         As the ‘interpreters’ of m<sup>6</sup>A marks, the individual reader proteins play prominent roles  
403 in modulating gene expression. Generally speaking, in HeLa and 293T cells, YTHDF1 binding  
404 correlates with increased translational efficiency, YTHDF2 binding accelerates mRNA decay, and

405 YTHDF3 may serve as a cofactor to assist the other reader protein function [1-4,19,20,54].  
406 However, other roles for these factors are rapidly emerging, particularly in the context of cell  
407 stress, infection, or in the control of specific transcripts [7,13,15,23-26,28,54,55]. Furthermore,  
408 m<sup>6</sup>A is enriched in certain tissues, and different m<sup>6</sup>A patterns have been found depending on  
409 the tissue and developmental stage [42,56]. Intriguingly, a recent study showed that hypoxia  
410 increases global m<sup>6</sup>A content of mRNA, with many m<sup>6</sup>A modified RNAs exhibiting increased  
411 stability, raising the possibility that m<sup>6</sup>A deposition could also stabilize transcripts during other  
412 forms of cellular stress [57]. In KSHV-infected iSLK.219 cells, YTHDF2 appears essential for the  
413 post-transcriptional accumulation of ORF50, a role seemingly at odds with its more canonical  
414 mRNA destabilizing function. In this regard, it was recently revealed that SV40 late transcripts  
415 contain multiple m<sup>6</sup>A sites, and that YTHDF2 strongly promotes SV40 replication [39]. Thus,  
416 YTHDF2 has been shown to play a pro-viral role in the context of both DNA and RNA viruses.  
417 Although we observed less dramatic viral gene expression phenotypes upon METTL3 depletion,  
418 it nonetheless was required for WT levels of progeny virion production in iSLK.219 and  
419 iSLK.BAC16 cells. An important consideration may be that m<sup>6</sup>A factors differentially impact  
420 specific KSHV transcripts, or play different roles at distinct times during infection. However,  
421 dissecting these possibilities is likely to be complicated by the changes in ORF50 expression  
422 (either positive or negative), which will have ripple effects on the entire lytic life cycle. Another  
423 relevant question is the extent to which m<sup>6</sup>A mediates its effects on KSHV gene expression co-  
424 transcriptionally versus post-transcriptionally. A recent report indicated that m<sup>6</sup>A is primarily  
425 installed in nascent mRNA in exons and affects cytoplasmic stability, but not splicing [16,47]. It  
426 has also been demonstrated that that m<sup>6</sup>A can be installed co-transcriptionally, and that

427 slowing the rate of RNA Pol II elongation enhances m<sup>6</sup>A modification of mRNAs in a manner  
428 that ultimately decreases translation efficiency [16,47]. These add to a growing body of  
429 literature indicating that the position of m<sup>6</sup>A in a transcript is a key feature impacting the  
430 functional consequence of the modification [1,3,6,7,13,20]. For example, m<sup>6</sup>A in the 3' UTR has  
431 been shown to recruit YTHDF1 and enhance translation initiation in HeLa cells, while deposition  
432 of m<sup>6</sup>A in the 5' UTR has been shown to enhance 5' cap independent translation [3,7,13].  
433 Whether these position-linked effects on translation extend to viral transcripts remains to be  
434 tested, although there does not appear to be a consistent enrichment in a particular region of  
435 viral mRNAs for the viruses analyzed thus far. In KSHV, m<sup>6</sup>A sites are found throughout viral  
436 ORFs, some of which also overlap with untranslated regions of other viral transcripts. As KSHV  
437 transcription depends on the host RNA Pol II, the speed of transcriptional elongation on viral  
438 mRNAs likely impacts co-transcriptional deposition and positioning of m<sup>6</sup>A, and thus may  
439 ultimately regulate translation efficiency of a given mRNA. Thus, in the context of KSHV  
440 reactivation, a wide variety of mechanisms exist through which m<sup>6</sup>A modification could impact  
441 the transcription and translation of viral mRNA. Deciphering these remains an important  
442 challenge for future studies, as we are currently in the early stages of understanding how this  
443 and other viruses interface with the m<sup>6</sup>A RNA modification pathway.

444

## 445 **Materials and Methods**

446 **Cell culture.** The renal carcinoma cell line iSLK.puro containing a doxycycline-inducible copy of  
447 ORF50, and the KSHV infected renal carcinoma cell lines iSLK.219 and iSLK.BAC16 bearing

448 doxycycline-inducible ORF50 [41] were cultured in Dulbecco's modified Eagle medium (DMEM;  
449 Invitrogen) with 10% fetal bovine serum (FBS; Invitrogen, HyClone) and 100 U/ml penicillin-  
450 streptomycin (Invitrogen). The KSHV-positive B cell line TREG-BCBL-1 containing a doxycycline-  
451 inducible version of ORF50 [52] was cultured in RPMI medium (Invitrogen) supplemented with  
452 20% FBS, 100 U/ml penicillin/streptomycin, and 200  $\mu$ M L-glutamine (Invitrogen). HEK293T cells  
453 (ATCC) were grown in DMEM (Invitrogen) supplemented with 10% FBS. To induce lytic  
454 reactivation of iSLK.219 cells,  $2 \times 10^6$  cells were plated in a 10 cm dish with 1  $\mu$ g/ml doxycycline  
455 (BD Biosciences) and 1 mM sodium butyrate for 72 hr. Lytic reactivation of TREG-BCBL-1 cells  
456 was achieved by treatment of  $7 \times 10^5$  cells/ml with 20 ng/ml 2-O-tetradecanoylphorbol-13-  
457 acetate (TPA, Sigma), 1  $\mu$ g/ml doxycycline (BD Biosciences), and 500 ng/ml ionomycin (Fisher  
458 Scientific) for 72 hr (western Blot blots for viral gene expression), or for 120 hr (supernatant  
459 transfer experiments).

460 **siRNA experiments.** For iSLK.219 cells, 100 pmol of siRNA was reverse transfected into  $5 \times 10^5$   
461 cells plated in a 6-well dish using Lipofectamine RNAimax (Life Technologies). 24 hr post  
462 transfection, cells were trypsinized and re-seeded on a 10 cm plate. The next day, a second  
463 transfection was performed on the expanded cells with the same concentration of siRNA (400  
464 pmol siRNA and  $2 \times 10^6$  cells). The following day, cells were lytically reactivated in a 10 cm plate.  
465 24 hr post-reactivation, cells were lysed in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1%  
466 Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) to evaluate knockdown  
467 efficiency. siRNA experiments in iSLK.BAC16 cells were conducted with the same siRNAs and  
468 concentrations. For experiments to assess mRNA and protein levels at 24 hr post-reactivation,  
469 one round of siRNA knockdown was performed 48 hr prior to reactivation, and knockdown

470 efficiency was evaluated at the time of cell harvest. For iSLK.BAC16 supernatant transfer  
471 experiments, two rounds of siRNA treatment were used, as described for iSLK.219 cells.

472 For TREX-BCBL-1 cells, 200 pmol of siRNA was nucleofected into  $2 \times 10^6$  cells using Lonza  
473 Cell Line Nucleofector Kit V and a Lonza Nucleofector 2b set to Program T001. After  
474 nucleofection, cells were immediately resuspended in 2.2 ml of RPMI media in a 12 well plate.  
475 48 hr later, 200 pmol of siRNA was added again to  $2 \times 10^6$  cells using the same protocol. 48 hr  
476 after the second transfection, cells were lysed in RIPA buffer and knockdown efficiency was  
477 analyzed by Western Blot. Cell viability post-nucleofection was assessed using a Countess II  
478 Automated Cell Counter (Life Technologies) with Trypan blue staining. For RT-qPCR  
479 experiments, two rounds of siRNA knockdown were performed under the identical conditions,  
480 except using an Invitrogen Neon Nucleofector with a single pulse of 1350 volts and pulse length  
481 of 40 ms.

482 The following Qiagen siRNAs were used: SI00764715 and SI04279121 targeting YTHDF1,  
483 SI04205761 targeting YTHDF3, custom siRNA targeting METTL3 (sequence targeted:  
484 CTGCAAGTATGTTCACTATGA). The following Dharmacon siRNAs were used: SMARTpool  
485 siGENOME (M-021009-01-0005), targeting YTHDF2, and siGENOME Non-Targeting siRNA Pool  
486 #1 (D0012061305). These same siRNAs were used in all three cell lines for the experiments in  
487 Figs 3-6. In addition, independent siRNAs (Qiagen SI04174534 targeting YTHDF2, Qiagen  
488 SI00764778 targeting YTHDF3 and Qiagen SI03650318 (negative control siRNA)) were used in S2  
489 Fig.

490 **Supernatant transfer assay and quantification of virion production.** Assays were performed as  
491 previously described [58]. Briefly, for iSLK.219 and iSLK.BAC16 cells, viral supernatant was  
492 collected 72 hr post-reactivation, filtered, and added to uninfected HEK293T cells by spinfection  
493 (1500 rpm, 90 minutes at room temperature). 12 hr later, supernatant was removed and  
494 replaced with fresh media, whereupon the cells were assessed for the successful transfer of the  
495 GFP-containing KSHV BAC 24 hr post-infection using a BD Accuri C6 flow cytometer. Briefly, cells  
496 were trypsinized, fixed in 4% paraformaldehyde, washed twice in PBS and resuspended in FACS  
497 Buffer (PBS with 1% FBS). Uninfected HEK293T cells were used to define the GFP negative  
498 population. The percentage of GFP expressing cells was quantified using FlowJo Software  
499 (FlowJo LLC). For virus produced in TREX-BCBL-1 cells, supernatant transfers were performed as  
500 in iSLK.219 cells, except the virus was transferred to HEK293T cells at 120 hr post-reactivation.  
501 To quantify virus produced in TREX-BCBL-1 cells, RNA was extracted from HEK293T cells 48 hr  
502 post-supernatant transfer, and viral gene expression was quantified by RT-qPCR using primers  
503 specific for LANA.

504 **Affinity purification and Western blotting.** Cell lysate was collected and analyzed as previously  
505 described [58]. Briefly, iSLK.219, iSLK.BAC16 or TREX-BCBL-1 cells were trypsinized, washed with  
506 PBS and lysed in RIPA buffer with protease inhibitors. After washing, 4X Laemmli sample buffer  
507 (Bio-Rad) was added to samples to elute bound proteins. Lysates were resolved by SDS-PAGE  
508 and western blots were carried out with the following antibodies: rabbit ORF50 (gift of  
509 Yoshihiro Izumiya, UC Davis), rabbit  $\alpha$ -K8.1 (1:10000, antibody generated for this study), rabbit  
510  $\alpha$ -ORF59 (1:10000, antibody generated for this study), rabbit  $\alpha$ -METTL3 (Bethyl, 1:1000), rabbit  
511  $\alpha$ -YTHDF1 (Proteintech, 1:1000), rabbit  $\alpha$ -YTHDF2 (Millipore, 1:1000), rabbit  $\alpha$ -YTHDF3 (Sigma,



512 1:1000), and goat  $\alpha$ -mouse and goat  $\alpha$ -rabbit HRP secondary antibodies (1:5000; Southern  
513 Biotech).

514 **4sU Labeling.** Following siRNA knockdown and 24 hr reactivation, iSLK.219 cells were pulse  
515 labeled with DMEM containing 500  $\mu$ M 4sU (Sigma) for 30 minutes, followed by PBS wash and  
516 immediate isolation of total RNA with TRIzol. 4sU isolation was performed as previously  
517 described [59]. 4sU isolated RNA was analyzed by RT-qPCR.

518 **RT-qPCR.** Total RNA was harvested using TRIzol following the manufacturer's protocol. Samples  
519 were DNase treated using Turbo DNase (Ambion), and cDNA was synthesized from 2  $\mu$ g of total  
520 RNA using AMV reverse transcriptase (Promega), and used directly for quantitative PCR (qPCR)  
521 analysis with the DyNAmo ColorFlash SYBR green qPCR kit (Thermo Scientific). All qPCR results  
522 were normalized to levels of 18s (except GAPDH where indicated) and WT or scramble control  
523 set to 1. RT-qPCR primers used in this study are listed in **S4 Table**.

524

525 **LC-MS/MS analysis of m<sup>6</sup>A.** Total RNA was isolated from iSLK219 cells with TRIzol reagent.  
526 Dynabeads mRNA purification kit (Ambion) was used to isolate polyA(+) RNAs from 100  $\mu$ g of  
527 total RNA according to the manufacturer. 100-200 ng of polyadenylated RNA was spiked with  
528 10  $\mu$ M of 5-fluorouridine (Sigma) and digested by nuclease P1 (1 U) in 25  $\mu$ L of buffer containing  
529 25 mM NaCl and 2.5 mM ZnCl<sub>2</sub> at 42 °C for 2-4 h, followed by addition of NH<sub>4</sub>HCO<sub>3</sub> (1 M, 3  $\mu$ L)  
530 and bacterial alkaline phosphatase (1 U) and incubation at 37 °C for 2 h. The sample was then  
531 filtered (Amicon 3K cutoff spin column), and 5  $\mu$ L of the flow through was analyzed by liquid

532 chromatography (LC) coupled to an Orbitrap-XL mass spectrometer (MS) equipped with an  
533 electrospray ionization source (QB3 Chemistry facility).

534 **m<sup>6</sup>A-RIP and m<sup>6</sup>A-RIP-sequencing.** Total cellular RNA (containing KSHV RNA) was extracted and  
535 purified by TRIzol and then DNase treated with Turbo DNase (Ambion). 30 µl protein G  
536 magnetic beads (Invitrogen) were blocked in 1% BSA solution for 1 hour, followed by incubation  
537 with 12.5 µg affinity-purified anti-m<sup>6</sup>A polyclonal antibody (Millipore) at 4°C for 2 hr with head-  
538 over-tail rotation. 100 µg purified RNA was added to the antibody-bound beads in IP buffer  
539 (150 mM NaCl, 0.1% NP-40, and 10 mM Tris-HCl [pH 7.4]) containing RNase inhibitor and  
540 protease inhibitor cocktail and incubated overnight at 4°C with head-over-tail rotation. The  
541 beads were washed three times in IP buffer, and then RNA was competitively eluted with 6.7  
542 mM m<sup>6</sup>A-free nucleotide solution (Sigma Aldrich). RNA in the eluate was phenol chloroform  
543 extracted and then reverse transcribed to cDNA for Real-Time qPCR analysis.

544 High-throughput sequencing of the KSHV methylome (m<sup>6</sup>A-seq) was carried following  
545 the previously published protocol [60]. In brief, 2.5 mg total cellular RNA was prepared from  
546 iSLK.219 cells that were either unreactivated, or reactivated for five days with doxycycline. RNA  
547 was isolated and DNase treated as in the m<sup>6</sup>A RIP, except the RNA was first fragmented to  
548 lengths of ~100 nt prior to immunoprecipitation with anti-m<sup>6</sup>A antibody (Synaptic Systems).  
549 Immunoprecipitated RNA fragments and comparable amounts of input were subjected to first-  
550 strand cDNA synthesis using the NEBNext Ultra RNA Library Prep Kit for Illumina (New England  
551 Biolabs). Sequencing was carried out on Illumina HiSeq2500 according to the manufacturer's  
552 instructions, using 10 pM template per sample for cluster generation, TruSeq SR Cluster kit v3  
553 (Illumina), TruSeq SBS Kit v3-HS (Illumina) and TruSeq Multiplex Sequencing primer kit

554 (Illumina). A reference human transcriptome was prepared based on the University of  
555 California, Santa Cruz (UCSC) and a reference KSHV transcriptome based on KSHV 2.0  
556 annotation [61]. Analysis of m<sup>6</sup>A peaks was performed using the model-based analysis of CHIP-  
557 seq (MACS) peak-calling algorithm. Peaks were considered significant if their MACS-assigned  
558 fold change was greater than four and individual FDR value less than 5%. Sequencing data are  
559 available on GEO repository (accession number GSE104621). Raw reads and alignment to the  
560 viral genome are shown in **S3 Table**.

561 **Statistical Analysis:** All results are expressed as means +/- S.E.M. of experiments independently  
562 repeated at least three times, except where indicated. Unpaired Student's t test was used to  
563 evaluate the statistical difference between samples. Significance was evaluated with P values  
564 <0.05.

## 565 **Acknowledgements**

566 This research was funded by NIH (<http://www.nih.gov/>) grants R01AI122528 to B.G. and  
567 HG008688 to C.H. B.G. and C.H. are investigators of the Howard Hughes Medical Institute. We  
568 wish to thank Divya Nandakumar for her assistance with the m<sup>6</sup>A-seq read mapping, as well as  
569 all members of the Glaunsinger and Coscoy labs for helpful comments and suggestions.

570

## 571 **References**

572

- 573 1. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression  
574 Regulation. *Cell*. 2017;169: 1187–1200. doi:10.1016/j.cell.2017.05.045

- 575 2. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent  
576 regulation of messenger RNA stability. *Nature*. 2013;505: 117–120.  
577 doi:10.1038/nature12730
- 578 3. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine  
579 Modulates Messenger RNA Translation Efficiency. *Cell*. 2015;161: 1388–1399.  
580 doi:10.1016/j.cell.2015.05.014
- 581 4. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through  
582 reversible m<sup>6</sup>A RNA methylation. *Nat Rev Genet*. 2014;15: 293–306.  
583 doi:10.1038/nrg3724
- 584 5. Zhao BS, Wang X, Beadell AV, Lu Z, Shi H, Kuuspalu A, et al. m(6)A-dependent maternal  
585 mRNA clearance facilitates zebrafish maternal-to-zygotic transition. *Nature*. 2017;542:  
586 475–478. doi:10.1038/nature21355
- 587 6. Xiao W, Adhikari S, Dahal U, Chen Y-S, Hao Y-J, Sun B-F, et al. Nuclear m(6)A Reader  
588 YTHDC1 Regulates mRNA Splicing. *Molecular Cell*. 2016;61: 507–519.  
589 doi:10.1016/j.molcel.2016.01.012
- 590 7. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, et al. 5' UTR m(6)A  
591 Promotes Cap-Independent Translation. *Cell*. 2015;163: 999–1010.  
592 doi:10.1016/j.cell.2015.10.012
- 593 8. Liu N, Pan T. N6-methyladenosine–encoded epitranscriptomics. *Cell Research*. 2016;23:  
594 98–102. doi:10.1038/nsmb.3162
- 595 9. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA  
596 structural switches regulate RNA-protein interactions. *Nature*. 2015;518: 560–564.  
597 doi:10.1038/nature14234
- 598 10. Zhou KI, Parisien M, Dai Q, Liu N, Diatchenko L, Sachleben JR, et al. N(6)-  
599 Methyladenosine Modification in a Long Noncoding RNA Hairpin Predisposes Its  
600 Conformation to Protein Binding. *J Mol Biol*. 2016;428: 822–833.  
601 doi:10.1016/j.jmb.2015.08.021
- 602 11. Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters RNA  
603 structure to regulate binding of a low-complexity protein. *Nucleic Acids Research*.  
604 2017;45: 6051–6063. doi:10.1093/nar/gkx141
- 605 12. Lewis CJT, Pan T, Kalsotra A. RNA modifications and structures cooperate to guide RNA-  
606 protein interactions. *Nat Rev Mol Cell Biol*. 2017;18: 202–210. doi:10.1038/nrm.2016.163
- 607 13. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian S-B. Dynamic m6A mRNA methylation  
608 directs translational control of heat shock response. *Nature*. 2015;526: 591–594.  
609 doi:10.1038/nature15377

- 610 14. Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene  
611 expression control. *Nat Rev Mol Cell Biol.* 2014;15: 313–326. doi:10.1038/nrm3785
- 612 15. Xiang Y, Laurent B, Hsu C-H, Nachtergaele S, Lu Z, Sheng W, et al. RNA m(6)A methylation  
613 regulates the ultraviolet-induced DNA damage response. *Nature.* 2017;543: 573–576.  
614 doi:10.1038/nature21671
- 615 16. Slobodin B, Han R, Calderone V, Vrieling JAFO, Loayza-Puch F, Elkon R, et al. Transcription  
616 Impacts the Efficiency of mRNA Translation via Co-transcriptional N6-adenosine  
617 Methylation. *Cell.* 2017;169: 326–337.e12. doi:10.1016/j.cell.2017.03.031
- 618 17. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates  
619 mammalian nuclear RNA N6-adenosine methylation. *Nat Chem Biol.* 2014;10: 93–95.  
620 doi:10.1038/nchembio.1432
- 621 18. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, et al. YTHDF2 destabilizes m(6)A-containing RNA  
622 through direct recruitment of the CCR4-NOT deadenylase complex. *Nat Commun.*  
623 2016;7: 12626. doi:10.1038/ncomms12626
- 624 19. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, et al. YTHDF3 facilitates translation and decay  
625 of N(6)-methyladenosine-modified RNA. *Cell Research.* 2017;27: 315–328.  
626 doi:10.1038/cr.2017.15
- 627 20. Li A, Chen Y-S, Ping X-L, Yang X, Xiao W, Yang Y, et al. Cytoplasmic m(6)A reader YTHDF3  
628 promotes mRNA translation. *Cell Research.* 2017;27: 444–447. doi:10.1038/cr.2017.10
- 629 21. Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N(6)-methyladenosine binding  
630 protein that regulates mammalian spermatogenesis. *Cell Research.* 2017;27: 1115–1127.  
631 doi:10.1038/cr.2017.99
- 632 22. Gokhale NS, Horner SM. RNA modifications go viral. *PLoS Pathog.* 2017;13: e1006188.  
633 doi:10.1371/journal.ppat.1006188
- 634 23. Gokhale NS, McIntyre ABR, McFadden MJ, Roder AE, Kennedy EM, Gandara JA, et al. N6-  
635 Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. *Cell Host*  
636 *Microbe.* 2016;20: 654–665. doi:10.1016/j.chom.2016.09.015
- 637 24. Kennedy EM, Bogerd HP, Kornepati AVR, Kang D, Ghoshal D, Marshall JB, et al.  
638 Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression. *Cell*  
639 *Host Microbe.* 2016;19: 675–685. doi:10.1016/j.chom.2016.04.002
- 640 25. Lichinchi G, Zhao BS, Wu Y, Lu Z, Qin Y, He C, et al. Dynamics of Human and Viral RNA  
641 Methylation during Zika Virus Infection. *Cell Host Microbe.* 2016;20: 666–673.  
642 doi:10.1016/j.chom.2016.10.002
- 643 26. Lichinchi G, Gao S, Saletore Y, Gonzalez GM, Bansal V, Wang Y, et al. Dynamics of the

- 644 human and viral m(6)A RNA methylomes during HIV-1 infection of T cells. *Nat Microbiol.*  
645 2016;1: 16011. doi:10.1038/nmicrobiol.2016.11
- 646 27. Gonzales-van Horn SR, Sarnow P. Making the Mark: The Role of Adenosine Modifications  
647 in the Life Cycle of RNA Viruses. *Cell Host Microbe.* 2017;21: 661–669.  
648 doi:10.1016/j.chom.2017.05.008
- 649 28. Tirumuru N, Zhao BS, Lu W, Lu Z, He C, Wu L. N(6)-methyladenosine of HIV-1 RNA  
650 regulates viral infection and HIV-1 Gag protein expression. *Elife.* 2016;5: 165.  
651 doi:10.7554/eLife.15528
- 652 29. Martínez-Pérez M, Aparicio F, López-Gresa MP, Bellés JM, Sánchez-Navarro JA, Pallás V.  
653 *Arabidopsis* m(6)A demethylase activity modulates viral infection of a plant virus and the  
654 m(6)A abundance in its genomic RNAs. *Proc Natl Acad Sci USA.* 2017.  
655 doi:10.1073/pnas.1703139114
- 656 30. Durbin AF, Wang C, Marcotrigiano J, Gehrke L. RNAs Containing Modified Nucleotides  
657 Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling. *MBio.* 2016;7:  
658 e00833–16. doi:10.1128/mBio.00833-16
- 659 31. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like  
660 receptors: the impact of nucleoside modification and the evolutionary origin of RNA.  
661 *Immunity.* 2005;23: 165–175. doi:10.1016/j.immuni.2005.06.008
- 662 32. Courtney DG, Kennedy EM, Dumm RE, Bogerd HP, Tsai K, Heaton NS, et al.  
663 Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication.  
664 *Cell Host Microbe.* 2017;22: 377–386.e5. doi:10.1016/j.chom.2017.08.004
- 665 33. Lavi S, Shatkin AJ. Methylated simian virus 40-specific RNA from nuclei and cytoplasm of  
666 infected BSC-1 cells. *PNAS.* 1975;72: 2012–2016.
- 667 34. Krug RM, Morgan MA, Shatkin AJ. Influenza viral mRNA contains internal N6-  
668 methyladenosine and 5'-terminal 7-methylguanosine in cap structures. *J Virol.* 1976;20:  
669 45–53. doi:10.1177/1091581816683642
- 670 35. Kahana C, Lavi S, Groner Y. Identification and mapping of N6 methyladenosine containing  
671 sequences in simian virus 40 RNA. *Nucleic Acids Research.* 1979;6: 2879–2899.
- 672 36. Moss B, Gershowitz A, Stringer JR, Holland LE, Wagner EK. 5'-Terminal and internal  
673 methylated nucleosides in herpes simplex virus type 1 mRNA. *J Virol.* 1977;23: 234–239.
- 674 37. Sommer S, Salditt-Georgieff M. The methylation of adenovirus-specific nuclear and  
675 cytoplasmic RNA. *Nucleic Acids Research.* 1976;3: 749–765.
- 676 38. Ye F, Chen ER, Nilsen TW. Kaposi's Sarcoma-Associated Herpesvirus Utilizes and  
677 Manipulates RNA N(6)-Adenosine Methylation To Promote Lytic Replication. *J Virol.*

- 678 2017;91. doi:10.1128/JVI.00466-17
- 679 39. Tsai K, Courtney DG, Cullen BR. Addition of m6A to SV40 late mRNAs enhances viral  
680 structural gene expression and replication. *PLoS Pathog.* 2018;14: e1006919.  
681 doi:10.1371/journal.ppat.1006919
- 682 40. Vieira J, O'Hearn PM. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-  
683 associated herpesvirus lytic gene expression. *Virology.* 2004;325: 225–240.  
684 doi:10.1016/j.virol.2004.03.049
- 685 41. Myoung J, Ganem D. Infection of Lymphoblastoid Cell Lines by Kaposi's Sarcoma-  
686 Associated Herpesvirus: Critical Role of Cell-Associated Virus. *J Virol.* 2011;85: 9767–  
687 9777. doi:10.1128/JVI.05136-11
- 688 42. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg  
689 S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq.  
690 *Nature.* 2012;485: 201–206. doi:10.1038/nature11112
- 691 43. Sun R, Lin SF, Gradoville L, Miller G. Polyadenylylated nuclear RNA encoded by Kaposi  
692 sarcoma-associated herpesvirus. *PNAS.* 1996;93: 11883–11888.
- 693 44. Bai Z, Huang Y, Li W, Zhu Y, Jung JU, Lu C, et al. Genomewide mapping and screening of  
694 Kaposi's sarcoma-associated herpesvirus (KSHV) 3' untranslated regions identify  
695 bicistronic and polycistronic viral transcripts as frequent targets of KSHV microRNAs. *J*  
696 *Virol.* 2014;88: 377–392. doi:10.1128/JVI.02689-13
- 697 45. Chandriani S, Ganem D. Array-based transcript profiling and limiting-dilution reverse  
698 transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated  
699 herpesvirus. *J Virol.* 2010;84: 5565–5573. doi:10.1128/JVI.02723-09
- 700 46. Lukac DM, Kirshner JR, Ganem D. Transcriptional activation by the product of open  
701 reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral  
702 reactivation in B cells. *J Virol.* 1999;73: 9348–9361.
- 703 47. Ke S, Pandya-Jones A, Saito Y, Fak JJ, Vågbø CB, Geula S, et al. m(6)A mRNA modifications  
704 are deposited in nascent pre-mRNA and are not required for splicing but do specify  
705 cytoplasmic turnover. *Genes Dev.* 2017;31: 990–1006. doi:10.1101/gad.301036.117
- 706 48. Cleary MD, Meiering CD, Jan E, Guymon R, Boothroyd JC. Biosynthetic labeling of RNA  
707 with uracil phosphoribosyltransferase allows cell-specific microarray analysis of mRNA  
708 synthesis and decay. *Nat Biotechnol.* 2005;23: 232–237. doi:10.1038/nbt1061
- 709 49. Woodford TA, Schlegel R, Pardee AB. Selective isolation of newly synthesized mammalian  
710 mRNA after in vivo labeling with 4-thiouridine or 6-thioguanosine. *Analytical*  
711 *biochemistry.* 1988;171: 166–172. doi:10.1016/0003-2697(88)90138-8

- 712 50. Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C, et al. Kaposi's  
713 Sarcoma-Associated Herpesvirus Open Reading Frame 50/Rta Protein Activates the  
714 Entire Viral Lytic Cycle in the HH-B2 Primary Effusion Lymphoma Cell Line. *J Virol.*  
715 2000;74: 6207–6212. doi:10.1128/JVI.74.13.6207-6212.2000
- 716 51. Brulois KF, Chang H, Lee AS-Y, Ensser A, Wong L-Y, Toth Z, et al. Construction and  
717 manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial  
718 chromosome clone. *J Virol.* 2012;86: 9708–9720. doi:10.1128/JVI.01019-12
- 719 52. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global Changes in Kaposi's  
720 Sarcoma-Associated Virus Gene Expression Patterns following Expression of a  
721 Tetracycline-Inducible Rta Transactivator. *J Virol.* 2003;77: 4205–4220.  
722 doi:10.1128/JVI.77.7.4205-4220.2003
- 723 53. Tan B, Liu H, Zhang S, da Silva SR, Zhang L, Meng J, et al. Viral and cellular N6-  
724 methyladenosine and N6,2'-O-dimethyladenosine epitranscriptomes in the KSHV life  
725 cycle. *Nat Microbiol.* 2018;3: 108–120. doi:10.1038/s41564-017-0056-8
- 726 54. Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification  
727 destabilizes developmental regulators in embryonic stem cells. *Nat Cell Biol.* 2014;16:  
728 191–198. doi:10.1038/ncb2902
- 729 55. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m6A Methyltransferase METTL3  
730 Promotes Translation in Human Cancer Cells. *Molecular Cell.* 2016;62: 335–345.  
731 doi:10.1016/j.molcel.2016.03.021
- 732 56. Wu R, Jiang D, Wang Y, Wang X. N (6)-Methyladenosine (m(6)A) Methylation in mRNA  
733 with A Dynamic and Reversible Epigenetic Modification. *Mol Biotechnol.* 2016;58: 450–  
734 459. doi:10.1007/s12033-016-9947-9
- 735 57. Fry NJ, Law BA, Ilkayeva OR, Holley CL, Mansfield KD. N(6)-methyladenosine is required  
736 for the hypoxic stabilization of specific mRNAs. *RNA.* 2017;23: 1444–1455.  
737 doi:10.1261/rna.061044.117
- 738 58. Davis ZH, Verschueren E, Jang GM, Kleffman K, Johnson JR, Park J, et al. Global mapping  
739 of herpesvirus-host protein complexes reveals a transcription strategy for late genes.  
740 *Molecular Cell.* 2015;57: 349–360. doi:10.1016/j.molcel.2014.11.026
- 741 59. Abernathy E, Gilbertson S, Alla R, Glaunsinger B. Viral Nucleases Induce an mRNA  
742 Degradation- Transcription Feedback Loop in Mammalian Cells. *Cell Host Microbe.*  
743 2015;18: 243–253. doi:10.1016/j.chom.2015.06.019
- 744 60. Dominissini D, Moshitch-Moshkovitz S, Salmon-Divon M, Amariglio N, Rechavi G.  
745 Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on  
746 immunocapturing and massively parallel sequencing. *Nat Protoc.* 2013;8: 176–189.  
747 doi:10.1038/nprot.2012.148



748 61. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, et al. KSHV 2.0: a  
749 comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using  
750 next-generation sequencing reveals novel genomic and functional features. *PLoS Pathog.*  
751 2014;10: e1003847. doi:10.1371/journal.ppat.1003847

752

### 753 **Figure Legends:**

754 **Fig 1. m<sup>6</sup>A increases upon KSHV reactivation.** (A) Schematic of the experimental setup.  
755 iSLK.219 cells were induced with doxycycline for 5 days to induce the lytic cycle, and total RNA  
756 was collected and subjected to oligo dT selection to purify poly(A) RNA. Polyadenylated RNA  
757 was spiked with 10uM of 5-fluorouridine and digested with nuclease P1 and alkaline  
758 phosphatase, and subjected to LC-MS/MS analysis. (B) Relative m<sup>6</sup>A content in iSLK.219 cells.  
759 The induced sample was normalized with respect to the uninduced sample (set to 1).

760

761 **Fig 2. KSHV mRNA contains m<sup>6</sup>A modifications.** (A) Two independent replicates of iSLK.219  
762 cells containing latent KSHV were treated with dox for 5 days to induce the viral lytic cycle  
763 (induced) or left untreated to preserve viral latency (uninduced). DNase-treated RNA was  
764 isolated and subjected to m<sup>6</sup>A-seq. Displayed are peaks with a fold change of four or higher,  
765 comparing reads in the m<sup>6</sup>A-IP to the corresponding input. (B) Overview of sequencing reads  
766 from induced and uninduced m<sup>6</sup>A IP samples, aligned to the ORF50 transcript and the  
767 annotated GG(m<sup>6</sup>A)C consensus motifs found in exon 2 of ORF50. (C) Cells were induced as in  
768 (A), and total RNA was subjected to m<sup>6</sup>A RIP, followed by RT-qPCR using primers for the  
769 indicated viral and cellular genes. Values are displayed as fold change over input, normalized to  
770 GAPDH. (D) Quantification of cellular m<sup>6</sup>A peaks from m<sup>6</sup>A-seq analysis.

771

772 **Fig 3. m<sup>6</sup>A and the reader YTHDF2 potentiate viral gene expression and virion production in**  
773 **iSLK.219 cells.** Cells were transfected with control scramble (scr) siRNAs or siRNAs against  
774 METTL3, YTHDF1, 2, or 3, then reactivated for 72 hr with doxycycline and sodium butyrate. (A)  
775 Knockdown efficiency was measured by western blot using antibodies for the indicated protein,  
776 with GAPDH serving as a loading control in this and all subsequent figures. (B) Viral supernatant  
777 was collected from the reactivated iSLK.219 cells and transferred to uninfected HEK293T  
778 recipient cells. 24 h later, the recipient cells were analyzed by flow cytometry for the presence  
779 of GFP, indicating transfer of infectious virions. (C) ORF50, ORF37 and K8.1 gene expression was  
780 analyzed by RT-qPCR from cells treated with the indicated siRNAs. Data are from 3 independent  
781 experiments. Unpaired Student's t test was used to evaluate the statistical difference between  
782 samples. Significance is shown for P values <0.05 (\*), ≤ 0.01 (\*\*), and ≤ 0.001 (\*\*\*). (D)  
783 Expression of the viral ORF50 and ORF59 proteins in cells treated with the indicated siRNAs was  
784 measured by western blot 72hr post-reativation. (E) Unreactivated iSLK.219 cells containing  
785 latent virus were treated with control scramble (scr) siRNAs or siRNAs targeting METTL3,  
786 YTHDF1, YTHDF2, or YTHDF3. The cells were then reactivated with dox and sodium butyrate for

787 48 hr and lytic reactivation was monitored by expression of the lytic promoter-driven red  
788 fluorescent protein. (F) Protein was harvested from the above described cells and subjected to  
789 western blot for ORF50 and the control GAPDH protein at 24 hr post-reactivation. (G-H)  
790 Uninfected iSLK.puro cells expressing DOX-inducible RTA were transfected with the indicated  
791 siRNAs for 48 h, then treated with dox for 24 hr to induce ORF50 expression. Knockdown  
792 efficiency (G) and ORF50 protein levels (H) were measured by western blot using antibodies for  
793 the indicated protein, with GAPDH serving as a loading control.

794

795 **Fig 4. Depletion of the m<sup>6</sup>A writer and readers does not impact ORF50 nascent transcription**  
796 **in iSLK.219 cells.** (A) Schematic of the experimental setup for measuring nascent RNA synthesis.  
797 Cells were transfected with the indicated siRNAs for 48h then reactivated for 24 hr with dox.  
798 4sU was added for 30 minutes, whereupon 4sU-labeled RNA was isolated using  
799 biotin/streptavidin affinity purification, reverse transcribed, and analyzed by RT-qPCR using  
800 primers specific to ORF50 or ORF37. (B-D) Levels of 4sU-labeled total ORF50 (B), ORF37 (C), and  
801 ORF50 transcribed from the viral genome (virus-derived) (D) determined as described above.  
802 Unpaired Student's t test was used to evaluate the statistical difference between samples.  
803 Significance is shown for P values <0.05 (\*), ≤ 0.01 (\*\*), and ≤ 0.001 (\*\*\*)).

804

805 **Fig 5. METTL3 and YTHDF2 are important for KSHV lytic replication in iSLK.BAC16 cells.** Cells  
806 were transfected with control scramble (scr) siRNAs or siRNAs against METTL3 or YTHDF2, then  
807 reactivated for 24 hr with doxycycline and sodium butyrate. (A) Knockdown efficiency was  
808 measured by western blot using antibodies for the indicated protein. (B) Viral supernatant was  
809 collected from the reactivated iSLK.BAC16 cells 72 hr post-reactivation and transferred to  
810 uninfected HEK293T recipient cells. 24 h later, the recipient cells were analyzed by flow  
811 cytometry for the presence of GFP, indicating transfer of infectious virions. (C) Quantification of  
812 supernatant transfer results from four independent experiments. (D) ORF50, ORF37, and K8.1  
813 gene expression 24 hr post-reactivation was analyzed by RT-qPCR from cells treated with the  
814 indicated siRNAs. Data for ORF50 are from five independent experiments, while ORF37 and  
815 K8.1 data are from four independent experiments. Unpaired Student's t test was used to  
816 evaluate the statistical difference between samples in panels C-D. Significance is shown for P  
817 values ≤ 0.01 (\*\*) and ≤ 0.001 (\*\*\*). (E) Western blots showing expression of the viral ORF50  
818 and ORF59 proteins at 24 hr post reactivation of iSLK.BAC16 cells treated with the indicated  
819 siRNAs.

820

821 **Fig 6. Increased viral gene expression upon m<sup>6</sup>A writer and reader depletion in TREX-BCBL-1**  
822 **cells.** (A) TREX-BCBL-1 cells were reactivated with dox for 72 hr, then total RNA was isolated  
823 and subjected to m<sup>6</sup>A RIP, followed by RT-qPCR for analysis of KSHV ORF50, GAPDH, and DICER.  
824 Values are displayed as fold change over input, normalized to the GAPDH negative control. Data  
825 are included from 3 biological replicates. (B-D) TREX-BCBL-1 cells were nucleofected with  
826 control scramble (scr) siRNAs or siRNAs specific to METTL3, YTHDF2, or YTHDF3, then lytically

827 reactivated by treatment with dox, TPA and ionomycin for 72 hr. (B) Knockdown efficiency of  
828 the m<sup>6</sup>A proteins relative to the loading control GAPDH was visualized by western blot. (C)  
829 Levels of the KSHV ORF50 and ORF59 proteins were assayed by western blot in the control and  
830 m<sup>6</sup>A protein-depleted samples. Additional replicates are shown in **S4 Fig**. (D) ORF50 gene  
831 expression was analyzed by RT-qPCR from cells treated with the indicated siRNAs and  
832 reactivated for 36 hr with dox, TPA and ionomycin. (E) Viral supernatant from the reactivated  
833 control or m<sup>6</sup>A protein depleted TREX-BCBL-1 cells was transferred to uninfected HEK293T  
834 recipient cells, whereupon transfer of infection was quantified by RT-qPCR for the viral LANA  
835 transcript 48 hr post supernatant transfer. Individual data points represent 3 independent  
836 experiments. Unpaired Student's t test was used to evaluate the statistical difference between  
837 samples. Significance is shown for P values <0.05, with \*\*\* representing P value ≤ 0.001.

838

### 839 **Supporting Information:**

840 **S1 Fig. Location of union FC>4 peaks within KSHV transcriptome.** Overview of sequencing  
841 reads aligned to regions of the KSHV transcriptome containing m<sup>6</sup>A modifications. Depicted are  
842 peaks with a fold change of four or higher in both replicates, comparing reads in the m<sup>6</sup>A-IP to  
843 the corresponding input. The blue and purple bars denote the sequences encompassed by the  
844 FC>4 peaks in each uninduced replicate (A), while the red and green colored bars denote the  
845 FC>4 peaks in each induced replicate (B). In the reference transcriptome, grey bars indicate  
846 annotated 3'UTRs or ncRNAs, while burgundy arrows depict ORFs. Note that the alignment of  
847 the ORF50 induced peaks can be found in Figure 2.

848 **S2 Fig.** (A) Independent siRNAs against YTHDF2 and YTHDF3 yield similar results as those shown  
849 in Fig 3. Cells were transfected with control scramble (scr) siRNAs (Qiagen SI03650318) or  
850 siRNAs against YTHDF2 (Qiagen SI04174534) or YTHDF3 (Qiagen SI00764778), then reactivated  
851 for 72 hr with doxycycline and sodium butyrate. Viral supernatant was collected from the  
852 reactivated iSLK.219 cells and transferred to uninfected HEK293T recipient cells. 24 h later, the  
853 recipient cells were analyzed by flow cytometry for the presence of GFP, indicating transfer of  
854 infectious virions. Data are from 2 independent experiments, with each replicate shown. (B)  
855 ORF50 and ORF37 gene expression was analyzed by RT-qPCR from the above cells at the time of  
856 supernatant transfer. (B) Viability of iSLK.BAC16 and iSLK.219 cells following siRNA transfection.  
857 Cells were transfected with the indicated siRNAs for 48 h, followed by lytic reactivation with  
858 dox and sodium butyrate for 48 h. Cells were collected and diluted 1:1 with Trypan blue prior to  
859 counting on a Countess II Automated Cell Counter. One representative experiment is shown.

### 860 **S3 Fig. Impact of METTL3 depletion on isolation of m<sup>6</sup>A modified mRNA in iSLK.BAC16 cells**

861 iSLK.BAC16 cells were subject to siRNA knockdown using METTL3 or control siRNA for 48 hr.  
862 Cells were reactivated for 24 hr with dox. (A) Western blot for knockdown efficiency at time of  
863 harvest. (B) Total RNA from harvested cells was then subject to m<sup>6</sup>A RIP RT-qPCR for the viral  
864 transcript ORF50 and cellular transcripts SON (m<sup>6</sup>A modified) and GAPDH (unmodified). Data  
865 shown are from 5 independent experimental replicates.

866 **S4 Fig.** (A) Quantification of cell viability following siRNA nucleofection and reactivation in TREX-  
867 BCBL-1 cells. TREX-BCBL-1 cells were nucleofected twice with the indicated siRNAs as described  
868 in the methods, and then reactivated for 36 hr with dox, PMA and ionomycin. Cells were  
869 collected and diluted 1:1 with Trypan blue prior to counting on a Countess II Automated Cell  
870 Counter. Viability from three independent experiments is depicted in the bar graphs. Unpaired  
871 Student's t test was used to evaluate the statistical difference between samples. Significance is  
872 shown for P values <0.05 (\*). (B) Western blots from replicate experiments showing viral ORF50  
873 and ORF59 protein levels in TREX-BCBL-1 cells treated with the indicated siRNAs and  
874 reactivated with dox, TPA, and ionomycin as described in Fig. 6C. (C) Western blots showing  
875 viral ORF50 and ORF59 protein levels in TREX-BCBL-1 cells treated with the indicated siRNAs for  
876 72 h prior to reactivation with TPA and ionomycin.

877 **S5 Fig. No changes in the levels of writers and readers following KSHV lytic reactivation**

878 iSLK.BAC16, iSLK.219 or TREX-BCBL-1 cells were reactivated where indicated with dox for 24 or  
879 48 hr, at which point cells were harvested and lysates were analyzed by Western blot for  
880 METTL3, YTHDF2, YTHDF3, and the GAPDH loading control.

881

882

883 S1. Table: Full list of FC>2 peaks within KSHV transcripts in induced and uninduced samples.

884 S2. Table: Full list of FC>4 peaks within host transcripts in induced and uninduced samples.

885 S3. Table: Read counts and alignment to the KSHV genome.


886 S4. Table: List of RT-qPCR primers used in this study.

Primer	Sequence (5'-3')	Orientation F: Forward R: Reverse
vIL6	CGGTTCACTGCTGGTATCTG	F
vIL6	CAGTATCGTTGATGGCTGGT	R
ORF57	TTTGACGAATCGAGGGACGACG	F
ORF57	GCAGTTGAGAACGACCTTGAGAT	R

ORF37	TGGGCGAGTTTATTGGTAGTGAGG	F
ORF37	CTCCACTAGACAGCAGATGTGG	R
K8.1	TCCCTAACGGGACCAGACT	F
K8.1	ACCCAGAGGCAGACGTATCT	R
PAN	TAATGTGAAAGGAAAGCAGCGCCC	F
PAN	CATTTAGGGCAAAGTGGCCCGATT	R
vGPCR	GTGCCTTACACGTGGAACGTT	F
vGPCR	GGTGACCAATCCATTTCCAAGA	R
K1	CCAAACGGACGAAATGAAAC	F
K1	TGTGTGGTTGCATCGCTATT	R
GAPDH	CGGAGTCAACGGATTTGGTCGTAT	F
GAPDH	AGCCTTCTCCATGGTGGTGAAGAC	R
ORF50	CGCAATGCGTTACGTTGTTG	F

ORF50	GCCCGGACTGTTGAATCG	R
ORF50 viral	GAGTCCGGCACACTGTACC	F
ORF50 viral	AAACTGCCTGGGAAGTTAACG	R
DICER	TGCTATGTCGCCTTGAATGTT	F
DICER	AATTTCTCGATAGGGGTGGTCTA	R
18s	GTAACCCGTTGAACCCCAT	F
18s	CCATCCAATCGGTAGTAGCG	R
LANA	TGGCCCATCTCGCGAATA	F
LANA	AACGCGCCTCATACGAACTC	R

A



B

